

# Index

- A**
- AAV. *See* Adeno-associated virus
  - ABCA5, 120
  - ABR. *See* Auditory brainstem response
  - AC6, 63
  - ACAN, 276
  - ACOT7, 120
  - ADAM10, 303
  - Adeno-associated virus (AAV)
    - channelrhodopsin delivery for optogenetic cochlear implant, 330–331
    - gene therapy vectors, 310–311
  - Adenovirus
    - channelrhodopsin delivery for optogenetic cochlear implant, 331
    - gene therapy vectors, 310
  - ADE, 117
  - ADGRV1, 61–63, 65, 71, 119, 122, 155–156
  - ADNSHL. *See* Autosomal dominant nonsyndromic hearing loss
  - Age-related hearing loss (ARHL)
    - animal models, 276–279
    - cochlear efferent protective functions, 183–184
    - dementia association, 279–280
    - epidemiology, 224–226, 272–273
    - genome-wide association studies, 273–276
    - hidden hearing loss, 236
    - overview, 271–272
    - pathology, 272–273
    - prospects for study, 279
    - treatment and prevention, 280–281
  - ALDOB/C, 119
  - Alport syndrome, epidemiology, 223
  - Alström syndrome, 47
  - Aminoglycoside-induced hearing loss
    - epidemiology, 224
    - hair cell entry, 257–259
    - hidden hearing loss, 237
    - macrophage response, 288
    - mechanisms, 259–260
    - otoprotection
      - BLB drug transport modulation, 260
      - cell death pathway targeting, 262
      - challenges, 263–264
      - drug discovery
        - cell lines, 261
        - zebrafish, 261
      - GV1001, 262
      - hydrogen therapy, 262
      - MET channel blocking, 260
      - ototoxic drug design, 261
      - strategies, 260
      - ototoxin tracking in inner ear, 255–257
      - overview, 253–255
    - Ankle link, hair bundle, 61–63
    - ANXA5, 120
    - ARHL. *See* Age-related hearing loss
    - ARNSHL. *See* Autosomal recessive nonsyndromic hearing loss
    - ATOH1, 280
    - Atoh1*, 310, 313–314
    - ATP2B2, 64, 119–120, 123
    - Auditory brainstem response (ABR), hidden hearing loss
      - diagnosis, 242–243
    - AUT00063, 280
    - Autosomal dominant nonsyndromic hearing loss, (ADNSHL), epidemiology, 220
    - Autosomal recessive nonsyndromic hearing loss (ARNSHL), epidemiology, 219–220

**B**

    - Bardet–Biedl syndrome (BBS), 47
    - Basilar membrane (BM), length and cochlear frequency tuning, 15, 19, 24
    - Bazooka, 50–51
    - BBS. *See* Bardet–Biedl syndrome
    - BDNF, 315–316
    - BM. *See* Basilar membrane
    - BOR syndrome. *See* Branchio-oto-renal syndrome
    - Branchio-oto-renal (BOR) syndrome, epidemiology, 223
    - Bullae, evolution, 5

**C**

    - CALB1, 120
    - CAPZA1, 116
    - CAPZA2, 116
    - CAPZB, 116, 124
    - Carbonic anhydrase, 120
    - CCL2, 291
    - CD1, 84
    - CD2, 69–70, 84
    - CD3, 69, 84
    - CDH23, 68–71, 93, 104, 119, 122, 156
    - CDHR15, 155
    - CDHR23, 155
    - Celsr*, 43
    - CGRP, 183
    - Channelrhodopsin, 327–329

## Index

- Charcot–Marie–Tooth disease, 236–237  
CHARGE syndrome, 220  
Chudley–McCullough syndrome (CMCS), 52  
CI. *See* Cochlear implant  
CIB2, 84–85, 106  
Cimetidine, 258  
Cisplatin-induced hearing loss  
  hair cell entry, 257–259  
  mechanisms, 259–260  
  otoprotection  
    BLB drug transport modulation, 260  
    cell death pathway targeting, 262  
    challenges, 263–264  
    drug discovery  
      cell lines, 261  
      zebrafish, 261  
    GV1001, 262  
    hydrogen therapy, 262  
    MET channel blocking, 260  
    ototoxic drug design, 261  
    strategies, 260  
  ototoxin tracking in inner ear, 255–257  
  overview, 253–255  
CKB, 119  
Clarin-1, 156  
Clathrin, 122  
CLIC5, 65, 116  
CLRN1, 104  
CMCS. *See* Chudley–McCullough syndrome  
CMV. *See* Cytomegalovirus  
Cochlear implant (CI)  
  indications, 325–326  
  optogenetics  
    electrical stimulation comparison, 333–334  
    microLEDs, 332–333  
    overview, 327  
    prospects, 334  
    tuning, 327–329  
  overview, 325–327  
  virus vectors for channelrhodopsin delivery to cochlea  
    adeno-associated virus, 330–331  
    adenovirus, 331  
    biosafety, 331–332  
    lentivirus, 331  
    overview, 329–330  
Cochlear synaptopathy  
  gene therapy, 316  
  hidden hearing loss, 237–239  
Collagen, gene mutations in hearing loss, 223  
Connexins  
  ATP release, 201  
  calcium signaling in development, 201–206  
  domains, 193  
  expression in cochlea, 196–197  
  gap junctions in cochlea, 194–196  
  gene therapy, 317–318  
  genes, 193  
  mouse models of nonsyndromic deafness, 199–201  
  mutations and hereditary hearing loss, 197–199  
  nutrient supply to organ of Corti, 196  
  overview of cochlear function, 191–194  
Convergence and extension, cochlear outgrowth, 42  
CREATE, 330  
CRISPR/Cas9, gene therapy, 319–320  
CSC-L1, 80  
CSC-L2, 80  
*CtBP2*, 149  
CTR1, 258  
CX3CL1, 289, 291  
CX3CR1, 289, 291  
Cytomegalovirus (CMV), 227
- D**  
*Dapl*, 49  
*Dchs1*, 43  
DCTN1, 121  
DCTN2, 121  
Deafness, epidemiology  
  age-related hearing loss, 224–226, 272–273  
  aminoglycoside-induced hearing loss, 224  
  infectious hearing loss, 227–228  
  noise-induced hearing loss, 228–229  
  nonsyndromic hearing loss  
    autosomal dominant nonsyndromic hearing loss, 220  
    autosomal recessive nonsyndromic hearing loss,  
      219–220  
    X-linked nonsyndromic hearing loss, 220  
  otosclerosis, 226  
  overview, 217–218  
  syndromic hearing loss  
    Alport syndrome, 223  
    branchio-oto-renal syndrome, 223  
    Jervell and Lange–Nielsen syndrome, 222  
    mitochondrial diseases, 223  
    overview, 220–222  
    Pendred syndrome, 222  
    Stickler syndrome, 222–223  
    Treacher Collins syndrome, 223  
    Usher syndrome, 222  
    Waardenburg syndrome, 222  
Dementia, age-related hearing loss association, 279–280  
DFNB7, 80  
DFNB11, 80  
DFNB48, 84  
DFNB84, 64  
*DIAPH1*, 44  
Dlg, 51  
*Dsh1*, 43, 46  
*Dsh2*, 43, 46  
DSTN, 117  
*Dvl*, 50  
Dynein, 121
- E**  
EF1 $\alpha$ , 312  
Efferent innervation, cochlea

- acetylcholine inhibition, 175, 178–181, 184
  - aging effects, 179–180
  - auditory nerve responses and otoacoustic emissions
    - lateral olivocochlear afferents, 180–181
    - noise responses, 181–182
    - quiet responses, 180
  - development and maturation, 179
  - electrophysiology, 177–179
  - GABA inhibition, 179
  - modulation, 179
  - overview, 175–176
  - pathology, 184
  - perceptual effects
    - hearing in noise, 182
    - mutant mouse strain studies, 183
    - selective attention, 182–183
  - perceptual learning role, 184
  - prospects for study, 184–185
  - protective functions
    - age-related hearing loss, 183–184
    - noise, 183
  - ultrastructure, 176–177
  - EFR. *See* Envelope following response
  - EGFR, 303
  - Endocochlear potential (EP), evolution, 8–10
  - Envelope following response (EFR), hidden hearing loss
    - diagnosis, 243
  - EP. *See* Endocochlear potential
  - Eps8, 52
  - EPS8L2, 116
  - Esketamine, hidden hearing loss management, 246
  - ESPN-1, 69
  - ESPNL, 69
  - ESRRG*, 276
  - Evolution, cochlea
    - bony invasions, 7
    - bullae, 5
    - coiling, 6–7
    - endocochlear potential, 8–10
    - hair cells, 7–8
    - impedance matching between middle and inner ear, 3–5
    - lagner macula loss, 10
    - length, 6–7, 11
    - organ of Corti, 7
    - phylogenetic tree of mammals, 2–3
    - pinnae, 5–6
    - regenerative capacity loss, 10–11
  - EYAI*, 223
  - F**
  - Fat*, 43
  - FBXO2, 121
  - FDPS, 120
  - FGF-2, 303
  - FGF3*, 44
  - FOX11*, 44
  - Frz*, 43, 46
  - FSCN1, 117
  - FSCN2, 116–117
  - Frz*, 49–50
  - G**
  - GAKIN, 51
  - Gap junctions. *See* Connexins
  - GAPDH, 119
  - GDI1, 121
  - GDI2, 121
  - Gene therapy
    - applications
      - hair-cell regeneration, 313–315
      - hidden hearing loss and cochlear synaptopathy, 316
      - spiral ganglion neuron preservation and regeneration, 315–316
  - CRISPR/Cas9, 319–320
  - deafness treatment
    - GJB2*, 317–318
    - TMC1, 318–319
    - Usher syndrome, 317–318
    - VGLUT3, 317
  - delivery to cochlea, 312–313
  - genetic regulatory elements, 311–312
  - vectors, 310–311
- GFAP, 315
- GJB2*, 197–201, 203, 219–221, 317–318
- GJB3*, 198
- GJB4*, 198
- GJB6*, 198
- GLI3*, 44
- Gpsm2–LGN
  - cytoskeletal remodeling, 52–53
  - hair bundle, control of movement and shape, 47–49
  - inner hair cell function, 52
- GPX1, 119
- GPX2, 119
- GPX4, 119
- GRM7*, 275
- GSN, 116–117
- GV1001, 262
- H**
- Hair bundle
  - active bundle motion
    - bifurcation theory, 34–36
    - biophysical models, 33–34
    - overview, 28–30
  - calcium feedback, 32
  - components
    - actin and actin-associated proteins, 116–118
    - adhesion molecules, 119
    - antioxidant proteins, 119
    - chaperones, 119
    - consensus proteome, 114–116
    - glycocalyx, 123–124

## Index

- Hair bundle (*Continued*)
    - ion channels, 120
    - lipid metabolism proteins, 120
    - lipids, 123
    - membrane-associated proteins, 120
    - metabolic enzymes, 119–120
    - microtubules and axonemes, 120–121
    - otolithic membrane and extracellular matrix, 121
    - protein complexes, 122–123
  - coupled arrays, 36–37
  - Gpsm2–LGN and PAR complex control of movement and shape, 47–49
  - links
    - ankle links, 61–63
    - kinocilial links, 69–70
    - overview of types, 59–60
    - prospects for study, 71, 73
    - shaft connectors, 63–65
    - tip links, 67–69, 72
    - top connectors, 65–67
    - transient lateral links, 70–71
  - macrophage interactions
    - birds, 292
    - regeneration studies, 292–294
    - zebrafish, 292, 294
  - molecular motors in adaptation, 31–32
  - nonlinear mechanics, 28, 34
  - planar cell polarity and orientation, 46–47
  - protein synthesis and turnover, 121
  - signaling, 121–122
  - trafficking, 122
  - transduction complex gating, 30–31
- Hair-cell regeneration
- avian model
    - historical perspective, 299–300
    - mitotic and nonmitotic regeneration, 300–302
    - modes of regeneration, 304–305
    - prospects, 305–306
    - stem cells, 302–304
  - gene therapy, 313–315
  - macrophage studies, 292–294
- HARMONIN. *See* USH1C
- Hath1, 315
- HCN1, 95
- HHL. *See* Hidden hearing loss
- Hidden hearing loss (HHL)
- diagnosis
    - auditory brainstem response, 242–243
    - envelope following response, 243
    - middle ear muscle reflex, 243
  - etiology
    - aging, 235
    - aminoglycoside antibiotics, 237
    - noise, 235–236
    - peripheral neuropathy, 236–237
  - gene therapy, 316
  - mechanisms
    - cochlear synaptopathy, 237–239
    - demyelination, 240–241
    - hair cell dysfunction, 240, 242
    - overview, 233–235
    - prospects for study, 246
    - treatment
      - efferent feedback modulation, 244–246
      - neurotrophins, 244
- HO-1, 291
- Hopf bifurcation, hair bundle, 34–36
- HSP70, 119
- HSP90, 119
- Huperzine A, 280
- ## I
- Ift20*, 43
  - Ift25*, 43
  - Ift88*, 43
  - IGF-1, 303
  - IHC. *See* Inner hair cell
  - Inner hair cell (IHC)
    - afferent synapses
      - development
        - functions in pre-hearing cochlea, 146
        - morphological changes, 144–146
      - excitatory postsynaptic current drivers, 152
      - exocytosis mechanisms
        - calcium channels, 149–152
        - ribbon synapses, 147–149
      - gene discoveries
        - otoferlin, 154–155
        - Usher proteins, 155–156
        - VGLUT3, 155
      - overview, 141–144
      - prospects for study, 156
      - spiral ganglion afferent fibers
        - type I, 152–154
        - type II, 154
    - evolution, 7–8
    - mechanoelectrical transduction. *See* Mechanoelectrical transduction, hair cells
    - mosaic in cochlea, 45–46
    - TMC1/2 function
      - binding partners
        - CIB2, 84–85
        - LHPPL5, 84
        - PCDH15, 83–84
        - TMIE, 84
        - TOMT, 85
      - conductance, 88–89
      - discovery, 79–80
      - expression and localization, 80–82
      - gating, 88
      - mechanoelectrical transduction, current mediation, 82–83
      - molecular structure, 85–88
      - pore formation, 87
  - Ins, 51
  - ISG20*, 276

- J**  
Jervell and Lange–Nielsen syndrome (JLNS),  
epidemiology, 222  
JLNS. *See* Jervell and Lange–Nielsen syndrome
- K**  
*KCNE1*, 222  
*KCNJ10*, 44  
*KCNQ1*, 222  
*KCNQ4*, 89, 220  
Khc-73, 51  
*Kif3a*, 43  
Kinocilial link, hair bundle, 69–70
- L**  
Lagenar macula, loss in evolution, 10  
LDHA, 119  
Lentivirus  
channelrhodopsin delivery for optogenetic  
cochlear implant, 331  
gene therapy vectors, 310  
LHFPL5, 84, 96–98
- M**  
Macrophage, inner ear  
cochlea  
organ of Corti, 287  
supporting tissues, 287–288  
injury response  
cell survival influences, 291–292  
recruitment, 290–291  
sensory region, 288–289  
spiral ganglion, 289  
origin and distribution, 286  
overview, 285–286  
vestibular organs, 289  
hair cell interactions  
birds, 292  
regeneration studies, 292–294  
zebrafish, 292, 294  
MAGUK, 51  
Math1, 314  
Mechanoelectrical transduction, hair cells  
channels  
mechanosensitive channel criteria, 95–96  
pore-forming subunits, 96–104  
functions  
*CIB2*, 106  
LHFPL5, 96–98  
*PIP<sub>2</sub>*, 107  
*TMCl/2*, 101–104  
*TMIE*, 98–101  
*TOMT*, 106–107  
overview, 93–95  
TMC and current mediation, 82–83  
Meckel–Gruber syndrome (MKS), 47  
MELAS, 223  
MEMR. *See* Middle ear muscle reflex  
MERRF, 223  
MIDD, 223  
Middle ear muscle reflex (MEMR), hidden hearing loss  
diagnosis, 243  
MKS. *See* Meckel–Gruber syndrome  
*MT-RNR1*, 224  
Mud, 50  
*Myh10*, 44  
MYO1C, 116, 122  
MYO1H, 116, 122  
MYO3B, 116  
MYO5A, 116  
MYO6, 64–65, 71, 116–117  
MYO7A, 33, 62, 104, 106, 116, 122, 124  
MYO15A, 116
- N**  
*Nectin1*, 45–46  
*Nectin3*, 45–46  
NF- $\kappa$ B. *See* Nuclear factor- $\kappa$ B  
Noise-induced hearing loss  
cochlear efferent protective functions, 183  
epidemiology, 228–229  
hidden hearing loss, 235–236  
macrophage response, 288  
NOX3, 259  
NPTN, 66, 119  
NT3, 244, 315–316  
Nuclear factor- $\kappa$ B (NF- $\kappa$ B), 196  
NUDC, 121  
NUMA, 50
- O**  
OAE. *See* Otoacoustic emission  
OCT1, 258–259  
OCT2, 258–259  
OHC. *See* Outer hair cell  
Optogenetics. *See* Cochlear implant  
Organ of Corti  
development, 42  
evolution, 7  
OSBP, 120  
OTOA, 66  
Otoacoustic emission (OAE)  
delay comparison between species, 15–16, 21–25  
frequency tuning and delay, 17–19  
tuning ratio  
noninvasive estimation, 21  
species invariance, 19–21  
units for reporting, 16–17  
Otoferlin, 154–155  
Otosclerosis, epidemiology, 226  
Outer hair cell (OHC)  
afferent synapses  
development  
functions in pre-hearing cochlea, 146  
morphological changes, 144–146

## Index

- Outer hair cell (OHC) (*Continued*)  
  excitatory postsynaptic current drivers, 152  
  exocytosis mechanisms  
    calcium channels, 149–152  
    ribbon synapses, 147–149  
  gene discoveries  
    otoferlin, 154–155  
    Usher proteins, 155–156  
    VGLUT3, 155  
  overview, 141–144  
  prospects for study, 156  
  spiral ganglion afferent fibers  
    type I, 152–154  
    type II, 154  
  electromotility  
    antiporter activity, 168–169  
    genetics  
      human, 169–170  
      mouse, 169  
    mechanisms, 167–168  
    overview, 165–167  
    pharmacology, 169  
    prestin  
      evolution, 170  
      membrane topology, 171–172  
      structure, 170–171  
    prospects for study, 172  
  evolution, 7–8  
  mechanoelectrical transduction. *See* Mechanoelectrical  
    transduction, hair cells  
  mosaic in cochlea, 45–46
- P**
- P21-activated kinase (PAK), 50  
PAICS, 120  
PAK. *See* P21-activated kinase  
Pallster–Hall syndrome (PHS), 44–45  
Par3, 50–51  
Par6, 50  
PAX3, 222  
PCDH15, 67–70, 83–84, 88, 93, 103–104, 119, 122  
PCDH20, 276  
PCP. *See* Planar cell polarity  
PDZD7, 62, 124  
PEBP1, 120  
Pendred syndrome, epidemiology, 222  
Peripheral neuropathy, hidden hearing loss, 236–237  
PFK, 119  
PGK1, 119  
PHS. *See* Pallster–Hall syndrome  
PI4KA, 120  
PIEZO2, 62, 70, 79, 95, 99  
Pinnae, evolution, 5–6  
Pins, 50–51  
PIP<sub>2</sub>, 64–65  
PIP<sub>3</sub>, 64  
PIPK2, 120  
PITPNA, 120  
PITPNB, 120  
PKA. *See* Protein kinase A  
PKC. *See* Protein kinase C  
PKD1, 95  
PKD2, 95  
Planar cell polarity (PCP)  
  gene mutations and cochlear effects, 43–44  
  hair bundle orientation, 46–47  
  oriented cell division and hair cell planar cell polarity,  
    50–51  
PLS1, 116–117  
POU3F4, 44, 220  
PPIB, 120  
Presbycusis. *See* Age-related hearing loss  
Prestin  
  evolution, 170  
  membrane topology, 171–172  
  outer hair cell electromotility role, 167–169  
  structure, 170–171  
Prickle, 51  
Protein kinase A (PKA), 63  
Protein kinase C (PKC), 50, 63  
PTK7, 44  
PTPRQ, 64–65, 71, 123
- R**
- Rab11, 52  
Rac1, 43  
RDX, 65, 116  
Regeneration. *See* Hair-cell regeneration  
RHO, 121  
Ribbon synapse, hair cell, 147–149  
RIBEYE, 149, 156  
RSPH4A, 121  
Rubella, 227
- S**
- Saddle node of invariant circle (SNIC) bifurcation, hair  
  bundle, 35–36  
SANS, 104  
SERCA, 201  
Shaft connector, hair bundle, 63–65  
SIX1, 223  
SIX5, 223  
SKP1A, 121  
SLC9A3R2, 117  
SLC9A9, 120  
SLC26A3, 168  
SLC26A4, 170, 221–222  
SLC26A5. *See* Prestin  
SLC26A6, 168  
SLC26A7, 168  
SNAP25, 148  
SNARE, 147–148  
SNIC bifurcation. *See* Saddle node of invariant circle  
  bifurcation  
SOD1, 119

- Sorcs2*, 52  
ST3GAL5, 123  
STARD10, 120  
Stbm, 51  
Stickler syndrome, epidemiology, 222–223  
STRC, 66–67, 73, 119–220  
Synapsin, 176
- T**
- TECTA, 121  
*Tecta*, 131, 134, 136  
TECTB, 121  
*Tectb*, 131, 136–137  
Tectorial membrane (TM)  
  electrokinetics, 133–134  
  longitudinal coupling via traveling waves, 135–138  
  physical properties, 131–133  
  porosity, 131–132  
  radial fibrillar structure, 134  
  structure and morphology, 129–131  
  wave mechanics, 134–135  
Tip link, hair bundle, 67–69, 72  
TM. *See* Tectorial membrane  
TMC1  
  binding partners  
    CIB2, 84–85  
    LHFPL5, 84  
    PCDH15, 83–84  
    TMIE, 84  
    TOMT, 85  
  discovery, 79–80  
  expression and localization, 80–82, 101, 103  
  gene therapy, 318–319  
  hair cell function  
    conductance, 88–89  
    gating, 88  
    mechanoelectrical transduction current mediation,  
      82–83, 103  
    pore formation, 87  
  mutations, 103–104  
  structure, 85–88, 102  
  superfamily, 80  
TMC2  
  binding partners  
    CIB2, 84–85  
    LHFPL5, 84  
    PCDH15, 83–84  
    TMIE, 84  
    TOMT, 85  
  expression and localization, 80–82, 101, 103  
  hair cell function  
    conductance, 88–89  
    gating, 88  
    mechanoelectrical transduction, current mediation,  
      82–83, 103  
    pore formation, 87  
  mutations, 103–104  
  structure, 85–88, 102  
  superfamily, 80  
  TMEM16, 80, 85–87, 257  
  TMHS. *See* LHFPL5  
  TMIE, 84, 98–101  
  TOMT, 85, 106–107  
  Top connector, hair bundle, 65–67  
  TORCH, 227  
  Treacher Collins syndrome, epidemiology, 223  
  *TRIOBP*, 275  
  TRPA1, 87, 95, 258  
  TRPC3, 95  
  TRPC6, 95  
  TRPM1, 95  
  TRPM6, 95  
  TRPM7, 95  
  TRPML3, 89, 95  
  TRPN1, 70, 95, 258–259  
  TRPV4, 95, 258  
  TRPV6, 95  
  TUBA, 120  
  TUBB, 120  
  Tuning ratio. *See* Otoacoustic emission  
  TWF2, 117, 124
- U**
- UBA1, 121  
USH1C, 62–63, 68, 71, 104, 106, 122  
USH1D, 155  
USH1E, 155  
USH1G, 69, 71  
USH1J, 85  
USH2A, 61, 63, 122, 155  
USH2C, 155  
USH3A, 156  
Usher syndrome  
  epidemiology, 222  
  gene therapy, 317–318
- V**
- Vangl2*, 43, 46, 50  
VEZTn62  
VGLUT3, 155, 317  
VLGR1, 61, 119
- W**
- Waardenburg syndrome (WS), epidemiology, 222  
*WFS1*, 44, 220  
WHIRLIN, 104, 106, 318  
WHRN, 62–63  
WNT, 303, 314  
*Wnt5a*, 43  
WS. *See* Waardenburg syndrome
- X**
- XBP-1, 237  
XIRP2, 116